Our analysis indicates that the increased TP53 mutation rates in the Chinese cancer patient populations was largely attributed to the higher mutation rates of TP53 in LUSC_CN, GACA_CN, ESCC_CN, LIHC_CN, and LUAD_CN after being integrated with the corresponding cancer epidemiology data (Supplementary Data 3_Epidemiological data_CN_ICD10). This evidence concerns the gene TP53 and cancer.